pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,552
stories
May 30, 26
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
stat
May 29, 26
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
biopharma dive
May 29, 26
Replimune will again submit its melanoma drug for approval
endpoints
May 29, 26
Allogene CEO to step down; Agios drug fails key test
biopharma dive
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
STAT+: Allogene CEO David Chang stepping down
stat
May 29, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 28, 26
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
biopharma dive
May 28, 26
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
endpoints
May 28, 26
GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis
endpoints
May 22, 26
FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
fda press
May 19, 26
STAT+: Marc Tessier-Lavigne addresses new book’s allegations about his conduct in Stanford misconduct case
stat
May 19, 26
BioMarin drug acquired in buyout misses goal in rare disease study
biopharma dive
May 19, 26
A migraine drugmaker heads to the public markets through reverse merger
biopharma dive
May 19, 26
STAT+: A new ranking of pharma companies by R&D performance
stat
May 19, 26
Relay drug shows early promise against rare blood vessel diseases
biopharma dive
May 19, 26
STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
stat
May 19, 26
The latest on Ebola: A travel ban and an old vaccine
stat
May 19, 26
BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
endpoints
May 19, 26
Opinion: Britain embraces a Massachusetts experiment on tobacco regulation — just as the state might roll it back
stat
May 19, 26
Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive
stat
May 18, 26
STAT+: Maryland state affordability board places a price cap on Ozempic
stat
May 18, 26
With no approved vaccine for Ebola outbreak, experts weigh testing a long shot
stat
May 18, 26
STAT+: Trump’s CMS to allow skimpier plans on ACA exchanges
stat
May 18, 26
STAT+: Why the WakeMed – Atrium Health hospital merger matters
stat
May 18, 26
STAT+: AstraZeneca picks up FDA approval for hypertension drug
stat
May 18, 26
FDA approves AstraZeneca’s new kind of hypertension drug
biopharma dive
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 18, 26
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
biopharma dive
May 18, 26
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
stat
← prev
page 46 of 52
next →